CBLB502, a slightly modified version of KMRC011 [17], significantly downregulates the TLR1, 2, 3, 4, 6, 7, 8, and 9 mRNA expression levels and had therapeutic effect in TNBC-induced colitis model by altering the NF-κB signaling pathway [20]. This evidence concerns the gene TLR1 and colitis.